Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 2
1990 1
1991 5
1992 5
1993 5
1994 5
1995 4
1996 4
1997 2
1998 8
1999 3
2000 4
2001 5
2002 1
2003 1
2004 1
2005 3
2006 2
2007 1
2008 1
2009 2
2010 1
2011 1
2012 2
2013 3
2014 1
2015 2
2019 2
2020 3
2024 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.
Zaher TF. Zaher TF. Int Urol Nephrol. 1998;30(2):193-6. doi: 10.1007/BF02550576. Int Urol Nephrol. 1998. PMID: 9607891 Clinical Trial.
PURPOSE: A study comparing intracorporeal injection of prostaglandin E1 (one-drug solution) and papaverine plus prostaglandin E1 (2-drug solution) for treatment of impotence. ...The complication rate was higher for the 2-drug solution. CONCLUSIO …
PURPOSE: A study comparing intracorporeal injection of prostaglandin E1 (one-drug solution) and papaverine plus pros …
Intracavernous injection of prostaglandin E1 plus procaine in the treatment of erectile dysfunction.
Schramek P, Plas EG, Hübner WA, Pflüger H. Schramek P, et al. J Urol. 1994 Oct;152(4):1108-10. doi: 10.1016/s0022-5347(17)32515-6. J Urol. 1994. PMID: 8072075 Clinical Trial.
Despite the availability of prostaglandin E1 for more than 7 years as a diagnostic and therapeutic tool in patients with erectile dysfunction, the problem of penile discomfort after prostaglandin E1 application has remained unsolved. In a randomized, d …
Despite the availability of prostaglandin E1 for more than 7 years as a diagnostic and therapeutic tool in patients with erect …
Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with combination of prostaglandin E1 and lidocaine in the treatment of organic impotence.
Kattan S. Kattan S. Urology. 1995 Jun;45(6):1032-6. doi: 10.1016/s0090-4295(99)80126-5. Urology. 1995. PMID: 7771004 Clinical Trial.
OBJECTIVES: To study the efficacy of lidocaine 1% in relieving pain associated with intracorporeal prostaglandin E1 and to assess its effect on the pharmacological erection. METHODS: Twenty-two patients who had previously experienced pain with intracorpore …
OBJECTIVES: To study the efficacy of lidocaine 1% in relieving pain associated with intracorporeal prostaglandin E1 and …
Non-surgical management of erectile dysfunction.
Levy A, Crowley T, Gingell C. Levy A, et al. Clin Endocrinol (Oxf). 2000 Mar;52(3):253-60. doi: 10.1046/j.1365-2265.2000.00954.x. Clin Endocrinol (Oxf). 2000. PMID: 10718821 Review.
Safe, non-surgical treatments with unequivocal efficacy are psychological therapy, intracorporeal injection of vasoactive drugs, transurethral vasodilators and oral sildenafil, all of which have been reported to have a 50-70% overall response rate. ...
Safe, non-surgical treatments with unequivocal efficacy are psychological therapy, intracorporeal injection of vasoactive drugs, tran …
Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.
Waldhauser M, Schramek P. Waldhauser M, et al. J Urol. 1988 Sep;140(3):525-7. doi: 10.1016/s0022-5347(17)41709-5. J Urol. 1988. PMID: 3045341 Clinical Trial.
The efficiency and side effects of a single dose of intracorporeally applied prostaglandin E1 (20 mcg.) in inducing penile erection were examined. ...At this dosage prostaglandin E1 was most effective in inducing artificial penile erection (11 o …
The efficiency and side effects of a single dose of intracorporeally applied prostaglandin E1 (20 mcg.) in inducing pen …
Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
Allen RP, Engel RM, Smolev JK, Brendler CB. Allen RP, et al. J Urol. 1992 Oct;148(4):1181-3. doi: 10.1016/s0022-5347(17)36853-2. J Urol. 1992. PMID: 1404632 Free article. Clinical Trial.
There was no statistical difference in rigidity or duration of erections between papaverine plus prostaglandin E1 and papaverine plus phentolamine plus prostaglandin E1. No patient reported significant penile pain with any of the injections. We conclud …
There was no statistical difference in rigidity or duration of erections between papaverine plus prostaglandin E1 and papaveri …
Current diagnosis and management of erectile dysfunction.
McMahon CG. McMahon CG. Med J Aust. 2019 Jun;210(10):469-476. doi: 10.5694/mja2.50167. Epub 2019 May 17. Med J Aust. 2019. PMID: 31099420 Review.
Between 60% and 65% of men with ED, including those with hypertension, diabetes mellitus, spinal cord injury and other comorbid medical conditions, can successfully complete intercourse in response to the phosphodiesterase type 5 inhibitors (PDE5i) sildenafil, tadalafil, vardenaf …
Between 60% and 65% of men with ED, including those with hypertension, diabetes mellitus, spinal cord injury and other comorbid medical cond …
Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
Shenfeld O, Hanani J, Shalhav A, Vardi Y, Goldwasser B. Shenfeld O, et al. J Urol. 1995 Sep;154(3):1017-9. J Urol. 1995. PMID: 7637045 Clinical Trial.
PURPOSE: A study was designed to compare intracorporeal injections of papaverine plus phentolamine (2-drug solution) and papaverine plus phentolamine and prostaglandin E1 (3-drug solution) for the treatment for impotence. ...CONCLUSIONS: Papaverine plus phent …
PURPOSE: A study was designed to compare intracorporeal injections of papaverine plus phentolamine (2-drug solution) and papaverine p …
Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence.
Kattan S, Collins JP, Mohr D. Kattan S, et al. Urology. 1991 Jun;37(6):516-8. doi: 10.1016/0090-4295(91)80314-w. Urology. 1991. PMID: 2038782 Clinical Trial.
This study was conducted to determine if patients with vasculogenic impotence who failed to respond to papaverine might respond to prostaglandin E1 and thus be salvaged from possible prosthetic surgery. A total of 54 patients with vasculogenic impotence were adminis …
This study was conducted to determine if patients with vasculogenic impotence who failed to respond to papaverine might respond to prosta …
Post-prostatectomy erectile dysfunction: contemporary approaches from a US perspective.
Hamilton Z, Mirza M. Hamilton Z, et al. Res Rep Urol. 2014 May 14;6:35-41. doi: 10.2147/RRU.S39560. eCollection 2014. Res Rep Urol. 2014. PMID: 24892031 Free PMC article. Review.
They work through cyclic adenosine monophosphate and cyclic guanine monophosphate pathways and are recommended in all forms of ED. Intracorporal injections or intraurethral use of vasoactive substances may be a good second-line therapy in men who do not experience improvem …
They work through cyclic adenosine monophosphate and cyclic guanine monophosphate pathways and are recommended in all forms of ED. Intrac …
79 results